Articles tagged with Blood Cancer
A recent study found that postmenopausal women taking anastrozole after tamoxifen treatment had a 38% reduced risk of breast cancer recurrence. Additionally, research indicates that blood transfusions may slightly increase cancer risk in the months following the procedure, likely due to underlying undiagnosed cancer.
Researchers found that a specific hormone, TNF-alpha, drives the JAK2 enzyme to cause an often deadly red blood cell cancer called polycythemia vera. The study showed mice with normal TNF-alpha production developed severe bone marrow fibrosis within weeks.
A recent survey reveals a significant gap in knowledge among primary care physicians regarding rare blood cancers like leukemia and lymphoma. The findings emphasize the importance of education and referrals to specialists in improving patient survival rates. As long-term cancer survivors, patients are at risk of developing second cance...
Researchers found that blocking blood vessel growth with an antiangiogenic agent can reduce inflammation and improve antitumor efficacy of oncolytic virus therapy. This approach may increase survival rates for patients with aggressive brain tumors.
Researchers develop compound that targets leukemia at stem-cell level, where malignancy is born, potentially leading to more effective treatments. DMAPT appears to be unique in its ability to kill both dormant and dividing cancer cells without harming healthy blood cells.
A long-term study found that stem cell transplant patients experience decreased sexual function and activity, particularly in females. While males recover partially over time, females remain compromised. The study suggests systemic therapies and chronic graft-versus-host disease contribute to sexual dysfunction.
Researchers at Purdue University have developed a new technology that detects cancer cells in the bloodstream by scanning surface veins. This non-invasive method allows for earlier diagnosis and more accurate monitoring of disease progression, enabling personalized treatment.
Dana-Farber Cancer Institute scientists have identified a protein that prevents the body's immune system from recognizing and attacking Hodgkin lymphoma cells. They are now investigating targeted therapies to disable this molecular 'bodyguard' and boost a patient's ability to fight the blood cancer.
A retrospective study published in The Lancet found no excess risk of cancer among individuals who received blood products from donors with previously diagnosed cancers. The study included over 12,000 exposed individuals and 342,082 unexposed individuals, concluding that long-term cancer survivors might be a safe donor group.
Researchers found bone marrow-derived endothelial progenitor cells (EPCs) play a critical role in early stages of tumor progression. Eliminating EPCs stops cancer growth by preventing blood vessel formation.
A blood test detecting tumor-related proteins may help monitor treatment effectiveness and predict cancer recurrence. Patients with low protein levels were more likely to remain in remission, while those with high increases were at higher risk of cancer return.
Researchers analyzed data on blood donations and recipients in Sweden and Denmark over 34 years, finding no link between cancer risk and blood from precancerous donors. The study provides valuable insights into the safety of blood transfusions and highlights the need for further research on chronic diseases.
Researchers at the National Cancer Institute found that children and young adults with sarcoma are at increased risk of developing thromboembolic events (blood clots) in their veins. The study found that patients whose cancer had spread beyond the original site were more likely to develop a blood clot.
Research suggests that phytochemicals in cruciferous vegetables, such as broccoli and watercress, can stop human prostate cancer cells from growing and inhibit the formation of blood vessels that feed tumors. This study provides promising preliminary evidence for the potential anti-cancer properties of these vegetables.
A new study examines partners of cancer survivors who underwent blood and marrow transplant, finding equal levels of mental health impairment, but with differing treatment outcomes and social support
Researchers have discovered that antibody signals can activate leukocytes to promote cell growth and increase blood supply in precancerous tissues, fueling cancer progression. Potential drugs already being tested may be able to block this pathway, offering a new therapeutic strategy for treating B cell lymphoma and autoimmune diseases.
A team of Boston scientists has discovered that FoxOs are critical in preventing some cancers, maintaining blood vessel stability, and keeping blood-forming stem cells healthy. The researchers found that mice lacking FoxO genes had serious blood abnormalities, including rapid division and depletion of stem cells.
Researchers at Georgetown University Medical Center found that young cancer survivors are at risk of developing unhealthy behaviors, including smoking, lack of exercise, and inadequate sun protection. The study suggests that these behaviors can increase the risk of cancer recurrence and chronic disease in adulthood.
Researchers found that galectin-3 breaks down protective shield MUC1, allowing cancer cells to attach to blood vessel wall and form tumours at secondary sites. The study has significant implications for future drug developments for cancer treatment.
A study presented at the American Society of Hematology Meeting shows Revlimid can provide long-term durable results in MDS patients, helping them achieve blood transfusion independence. After over two years of follow-up, two-thirds of patients were completely freed from the need for blood transfusions.
The study presents positive interim results of using ALDESORT to isolate cord blood stem cells, showing improved overall survival at 90.9% compared to a historical control group. The infusion of cells enriched with ALDESORT appears to improve the speed and efficacy of cord blood transplantations.
Studies presented at the 2006 Annual Meeting of the American Society of Hematology demonstrate significant gains in treating multiple myeloma and related blood cancers. New treatment regimens, including THALOMID, VELCADE, and REVLIMID, show promising results in both newly diagnosed and relapsed patients.
Researchers found that white blood cells in cancer-resistant mice can sense and kill cancer cells through a multi-step process, involving migration, recognition, and physical contact. The discovery suggests that some cancers may share common characteristics that make them vulnerable to this type of immune response.
The use of videoconferencing in a twinning program between Jordan and Canada improved patient care, compliance, and trust. The program showed positive impacts on treatment changes, second opinions, and introduction of new concepts in pediatric oncology.
Acute myelogenous leukemia (AML) patients who have multiple active molecular pathways in their blood and bone marrow samples tend to have a poorer prognosis. Targeting just one pathway is unlikely to be effective due to cross-activation, requiring the development of multi-drug therapies.
A team led by Berkeley Lab's Susan J. Fisher and Joe W. Gray aims to identify cancer-specific proteins and patterns in blood samples for early detection. By combining genome-wide studies with mass-spectrometry-based protein analysis, the team hopes to develop a more accurate test for all cancers.
A new protein in blood serum, human aspartyl beta-hydroxylase (HAAH), has shown promise as a sensitive and specific biomarker for early detection of prostate cancer. HAAH is overexpressed in at least 20 types of cancer and has been linked to tumor growth and invasiveness.
Researchers successfully transplanted white blood cells from cancer-resistant mice into normal mice, eradicating existing and preventing lethal doses of new aggressive cancers. This breakthrough study demonstrates the potential for cancer-resistant-cell therapy to treat highly aggressive types of cancer.
A recent study found that low folate levels and a common mutation in the MTHFR gene may lower the risk of bowel cancer. People with blood levels of folate between the highest and lowest were almost twice as likely to develop the disease compared to those at either extreme.
Researchers identified four genetic subtypes of multiple myeloma, each with distinct gene signatures that predict patient outcomes. The findings provide a clear path for targeted therapies and could lead to improved treatments for this incurable blood cancer.
The center will investigate disparities in modifiable risk factors for breast cancer, particularly among African-American women, and examine demographic, lifestyle, medical, and genetic profiles for obesity. The research aims to develop predictive models and biomarkers to improve early detection and treatment of breast cancer.
Researchers found that fibulins inhibit both tumor growth and blood-vessel formation in mice. The study showed that tumors producing fibulins grew up to 24-45% smaller than control tumors after three weeks.
Scientists have developed nanowire arrays that can detect multiple cancer markers with near-perfect selectivity. These devices can test a mere pinprick of blood in minutes, providing immediate scans and potentially tracking patients' health as treatment progresses.
The blood test aims to identify individuals with improper control of the growth-promoting gene insulin-like growth factor 2 (IGF-2), which is associated with a higher risk of colon cancer. If successful, the test could help monitor those who need invasive colonoscopy or suggest dietary changes to reduce their risk.
A new protein targets tumor vasculature by inducing coagulation when administered systemically, delaying tumor growth and producing some tumor regressions. The treatment shows promise for cancer therapy, adding a powerful punch to the fight against cancer.
A study found that patients with high circulating endothelial cell counts before treatment were more likely to have growing tumors, while those with low counts remained stable. This test may predict patient outcomes and survival, allowing doctors to tailor treatment and spare unnecessary side effects.
Researchers at Johns Hopkins Medicine have developed a new method to educate T-cells in the bone marrow, increasing their ability to recognize and kill cancer cells. The approach shows promise for treating myeloma and potentially other blood and solid tumors.
A 10-year study of 1,298,385 Koreans found that high sugar levels were associated with higher death rates from all cancers combined. The strongest associations were for pancreatic cancer in men and liver and cervix cancers in women.
A $9.7 million grant led by Fred Hutchinson Cancer Center aims to create reliable and inexpensive blood tests for early cancer detection. The collaboration involves institutions worldwide, with a focus on identifying serum biomarkers and protein patterns to detect disease at an early stage.
A study found that 23% of zoo workers handling primates showed reactivity to the SV40 virus, but most reactions were likely due to cross-reactivity with other polyomaviruses. The study suggests occupational exposure to SV40 among those working closely with nonhuman primates.
A recent study found that the Ras protooncogene induces inflammation via CXCL-8, a key factor in tumor growth and angiogenesis. Inhibition of CXCL-8 function led to decreased tumor angiogenesis, highlighting its potential as an anticancer therapeutic target.
Researchers found a link between chronic allergic stimulation and an increased risk of leukemia and non-Hodgkin's lymphoma in adults. Childhood eczema also appeared to increase the risk of this condition, although its impact is still relatively rare.
A team of researchers from MIT has identified three new carcinogens found in cigarette smoke as risk factors for bladder cancer in nonsmokers. The study, led by Professor Steven R. Tannenbaum, aimed to identify sources of exposure for non-smokers and highlights the importance of preventing cancer rather than treating it.
Researchers at Temple University's Sbarro Institute developed a new blood test that uses CDK9/CYCLIN T1 expression to accurately diagnose lymphoma cancer types and stages. The study, published in the Journal of Pathology, found that analyzing these molecules in a blood sample can pinpoint the presence of lymphoma with high accuracy.
Anal cancer rates have increased by 160% in men and 78% in women over the past 30 years, with African-American men showing a particularly sharp increase. Human papillomavirus (HPV) infection is necessary for most cases of anal cancer, but smoking also plays a significant role.
A Phase II clinical trial suggests that RAD001, targeting mTOR, can decrease uterine tumor size in recurrent endometrial cancer. The treatment offers new hope for patients with advanced and recurrent cases, which account for about 7,000 deaths annually.
A new study by Dr. Thomas Walle found that resveratrol, a widely sold dietary supplement, is unlikely to have an effect on breast and prostate cancers when consumed in the diet or as a supplement. However, it may still prevent cancers along the aerodigestive tract, suggesting further research is needed.
Researchers developed a biomarker to detect HBV mutations that speed up liver cancer development. Studies found HBV mutations predicted major liver disease, including liver cancer, up to eight years before diagnosis.
Researchers discovered that BCR/ABL oncogene blocks normal DNA repair mechanism, leading to genetic mutations and blast crisis. This breakthrough may lead to long-term treatment for chronic myelogenous leukemia, a fatal blood cancer affecting people over 40.
Researchers at Dana-Farber Cancer Institute have discovered that the MLL gene is necessary for the development of master stem cells that generate all mature blood cells. The study suggests that MLL is part of a select set of genes required for all definitive blood lineages in the embryo.
A new study by St. Jude/Mayo Clinic researchers found a direct link between the CBP gene and lymphoma development in mice, with the loss of CBP promoting T-cell lymphoma and cooperating with reduced p27Kip1 protein levels. The study suggests that CBP plays a role in cancer development despite normal p53 activity.
Researchers explored the potential of copper to control cancerous growth by depleting it of essential nutrients. Studies have shown that regulating copper levels can stop tumor growth, although no cures have been found yet, and further research is needed for a more comprehensive approach.
A study published in The Journal of the American Medical Association found that people with higher CRP levels were more likely to develop colorectal cancers over an 11-year period. Median CRP levels were higher among those who developed colon cancer, and inflammation was linked to increased risk without being mediated by diabetes.
Case Western Reserve University scientists identified a protein called clusterin that can signal cell distress and detect cancer. A simple blood test could potentially identify abnormal clusterin levels, indicating the presence of cancer.
Researchers at the University of Iowa have discovered a way to improve cancer immunotherapy by directing specific types of white blood cells to kill cancer cells. By using CpG ODN agents, doctors can gear up natural killer cells and granulocytes to work with antibodies to target cancer cells more effectively.
Researchers found that patients with smoking-related cancers had shorter telomeres than those without cancer, and that short telomeres were associated with a greater cancer risk. Smoking status significantly influenced the effect of short telomeres on cancer risk.
A new treatment, interleukin-11 (IL-11), has shown early promise in reducing the risk of infection in patients undergoing chemotherapy for blood cancer. Patients who received IL-11 experienced significantly fewer cases of bacterial infections compared to those who received a placebo.
Researchers discovered that the Id1 gene regulates angiogenesis in melanoma, breast, head and neck, brain, cervical, prostate, pancreatic, and testicular cancers by reducing thrombospondin-1 production. This reduction leads to increased tumor blood vessel formation.
A comprehensive periodontal examination can save lives by detecting undiagnosed protein S deficiency, a condition that causes thrombotic disorders and increases the risk of strokes and heart attacks. Early diagnosis is key to successful treatment outcomes and improved survival rates for patients with this condition.
A new computer-based algorithm identifies a distinct proteomic pattern that distinguishes malignant from benign tumours within the ovary with 100% sensitivity and 95% specificity. This technique may help screen for ovarian cancer in high-risk and general populations.